Prophylaxis of thrombosis induced by chemotherapy or central venous catheters;Doit-on prescrire une prophylaxie de la maladie thromboembolique aux patients porteurs d'un cathéter central et/ou recevant une chimiothérapie pour une tumeur solide ?

Presse Medicale

Volumn 36, Issue 2 I, 2007, Pages 225-234

  Voog, Éric ^a   Lazard, Éric ^a   Juhel, Laurence ^a  

^a CENTRE JEAN BERNARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CENTRAL VENOUS CATHETER; CHEMOTHERAPY; HUMAN; MEDICAL LITERATURE; MEDLINE; PATHOGENESIS; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS; CENTRAL VENOUS CATHETERIZATION; DRUG EFFECT; HEMOSTASIS; NEOPLASM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANTINEOPLASTIC AGENTS; CATHETERIZATION, CENTRAL VENOUS; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; NEOPLASMS; THROMBOEMBOLISM; THROMBOSIS;

EID: 34047142283     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2006.08.001     Document Type: Article

References (46)

1. Trousseau A. Phlegmasia alba dolens. Clinique Médicale de l'Hôtel Dieu de Paris (1868), New Sydenham Society London 695-727 (3)
2. Luzzatto G., and Schafer A.I. The prethrombotic state in cancer. Semin Oncol 17 (1990) 147-159
3. Green K.B., and Silverstein R.L. Hypercoagulability in cancer. Hematol Oncol Clin North Am 10 (1996) 499-530
4. Dhami M.S., and Bona R.D. Thrombosis in patients with cancer. Postgrad Med 93 (1999) 131-140
5. Sallah S., Wan Jim Y., and Nauven N.P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87 (2002) 575-579
6. Weiss R.B., Tormey D.C., Holland J.F., and Weinberg V.E. Venous thrombosis during multinodal treatment of primary breast carcinoma. Cancer Treat Rep 65 (1981) 677-679
7. Goodnough L.T., Saito H., Manni A., Jones P.K., and Pearson O.H. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 54 (1984) 1264-1268
8. Wall J.G., Weiss R.B., Norton L., Perloff M., Rice M.A., Korzun A.H., et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. Am J Med 87 (1989) 501-504
9. Saphner T., Tormey D.C., and Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9 (1991) 286-294
10. Von Tempelhoff G.F., Dietrich M., Hommel G., and Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophophamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 14 (1996) 2560-2568
11. Weijl N.I., Rutten M.F., Zwinderman A.H., Keizer H.J., Nooy M.A., Rosendaal F.R., et al. Thromboembolic events during chemotherapy for germ cell cancer : a cohort study and review of the literature. J Clin Oncol 18 (2000) 2169-2178
12. Levine M.N., Gent M., Hirsh J., Arnold A., Goodyear M.D., Hryniuk W., et al. The thrombogenic effect of anticancer drugs therapy in women with stage II breast cancer. N Engl J Med 318 (1988) 404-407
13. Pritchard K.I., Paterson A.H., Paul N.A., Zee B., Fine S., and Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 14 (1996) 2731-2737
14. Clahsen P.C., Van de Velde C.J., Julien J.P., Floiras J.L., and Mignolet F.Y. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 12 (1994) 1266-1271
15. Barbui T., Finazzi G., Grassi A., and Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factor a meta-analysis. Thromb Haemost 75 (1996) 368-371
16. Rosenzweig M.Q., Bender C.M., Lucke J.P., Yasko J.M., and Brufsky A.M. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 27 (2004) 185-190
17. Bohlius J., Langensiepen S., Schwarzer G., Seidenfeld J., Piper M., Bennett C., et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97 (2005) 489-498
18. McGee D.C., and Gould M.K. Preventing complications of central venous catheterization. N Engl J Med 348 (2003) 1123-1133
19. Balesteri L., De Cicco M., Matovic M., Coran F., and Morassut S. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Eur J Radiol 20 (1995) 108-111
20. Monreal M., Raventos A., Lerma R., Ruiz J., Lafoz E., Alastrue A., et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines. A prospective study. Thromb Haemost 72 (1994) 548-550
21. Von Tempelhoff G.F., Dietrich M., Hommel G., and Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophophamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 14 (1996) 2560-2568
22. Welch C.W., McKeel D.W., Silverstein P., and Walker H.L. The role of catheter composition in the development of thrombophlebitis. Surg Gynecol Obstet 138 (1974) 421-424
23. Mueller B.U., Skelton J., Callender D.P., Marshall D., Gress J., Longo D., et al. A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 10 (1992) 1943-1948
24. Lokich J.J., Bothe Jr. A., Benotti P., and Moore C. Complications and management of implanted venous access catheters. J Clin Oncol 5 (1985) 710-717
25. Hayward S.R., Ledgerwood A.M., and Lucas C.E. The fate of 100 prolonged venous access devices. Am Surg 56 (1990) 515-519
26. Luciani A., Clement O., Halimi P., Goudot D., Portier F., Bassot V., et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 3 (2001) 655-660
27. Haire W.D., Lieberman R.P., and Edney J. Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation. Cancer 66 (1990) 900-908
28. Ratcliffe M., Broadfoot C., Davidson M., Kelly K.F., and Greaves M. Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. Clin Lab Haematol 21 (1999) 353-357
29. Bern M.M., Lokich J.J., Wallach S.R., Bothe Jr. A., Benotti P.N., Arkin C.F., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112 (1990) 423-428
30. Boraks P., Seale J., Price J., Bass G., Ethell M., Keeling D., et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 101 (1998) 483-486
31. Heaton D.C., Han D.Y., and Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 32 (2002) 84-88
32. Couban S., Goodyear M., Burnell M., Dolan S., Wasi P., Barnes D., et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23 (2005) 4063-4069
33. Carr K.M., and Rabinowitz I. Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors. J Clin Oncol 18 (2000) 3665-3667
34. Masci G., Magagnoli M., Zucali P.A., Castagna L., Carnaghi C., Sarina B., et al. Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients : Can It Be Safely Associated With Fluorouracil-Based Chemotherapy?. J Clin Oncol 21 (2003) 736-739
35. Massicotte P., Julian J.A., Gent M., Shields K., Marzinotto V., Szechtman B., et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line related thrombotic complications in children: The PROTEKT study. Thromb Res 109 (2003) 101-108
36. Reichardt P., Kretzschmar A., Biakhov M., Irwin D., Slabber C., Miller L., et al. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight-heparin (dalteparin sodium) in preventing catheter-related complications (CRCs) in cancer patients with central venous catheters (CVCs). Proc Am Soc Clin Oncol. 21 (2002) 369a (abstr 1474)
37. Iniesta P., Garcia T., Ayala F., Macias J., Flores B., Cava C., et al. Dalteparin is effective as prophylaxis of central venous catheter-remated thrombosis in cancer patients. Proc Am Soc Clin Oncol. 22 (2003) 784a (abst 3151)
38. Verso M., Agnelli G., Bertoglio S., Di Somma F.C., Paoletti F., Ageno W., et al. Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients. J Clin Oncol 23 (2005) 4057-4062
39. Levine M., Hirsh J., Gent M., Arnold A., Warr D., Falanga A., et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 (1994) 886-889
40. Taylor S.G., Knuiman M.W., Sleeper L.A., Olson J.E., Tormey D.C., Gilchrist K.W., et al. six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol 7 (1989) 879-889
41. Mansour E.G., Gray R., Shatila A.H., Osborne C.K., Osborne C.K., Tormey D.C., et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med 320 (1989) 485-490
42. IBCSG. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320 (1989) 491-496
43. Fisher B., Redmond C., Legault-Poisson S., Dimitrov N.V., Brown A.M., Wickerham D.L., et al. Post-operative chemotherapy and tamoxifen compared with tamoxifene alone in the treatment of positive node breast cancer patients aged 50 years and older with tumours responsive to tamoxifen: results from the NSABP B16. J Clin Oncol 8 (1990) 1005-1018
44. Rivkin S.E., Green S., Metch B., Cruz A.B., Abeloff M.D., Jewell W.R., et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Orthod 1 (1994) 2078-2085
45. Fisher B., Dignam J., Wolmark N., DeCillis A., Emir B., Wickerham D.L., et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89 (1997) 1673-1682
46. Wils J.A., Bliss J.M., Marty M., Coombes G., Fontaine C., Morvan F., et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol 17 (1999) 1988-1998